Hepatocellular carcinoma with hepatic vein invasion should not be considered a contraindication for liver resection
Xiu‐Ping Zhang, Kang Wang, Zhen‐Hua Chen, Shu‐Qun Cheng – 20 November 2017
Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO
Zobair M. Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R. Lenderking, Anne Skalicky, Leah Kleinman, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Cynthia Levy, Christopher L. Bowlus, Kris Kowdley, Andrew J. Muir – 20 November 2017 – Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC‐specific patient‐reported outcome (PRO) instrument.
Correction
20 November 2017
Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome
Vian Azzu, Joshua E. Elias, Adam Duckworth, Susan Davies, Rebecca Brais, Dinakantha S. Kumararatne, Alexander E. S. Gimson, William J. H. Griffiths – 20 November 2017 – Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency characterized by antibody deficiency, recurrent bacterial infections, and autoimmunity. Advanced chronic liver disease occurs in a subset of patients with CVID and manifests with various histological features, such as nodular regenerative hyperplasia, inflammation, fibrosis, and cholangiopathy.
Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies
Tracey G. Simon, Lindsay Y. King, Dawn Q. Chong, Long H. Nguyen, Yanan Ma, Trang VoPham, Edward L. Giovannucci, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Hamed Khalili, Raymond T. Chung, Xuehong Zhang, Andrew T. Chan – 20 November 2017 – Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk.
Issue Information
20 November 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih‐Wei Lin, Yang Lei, Teresa I. Ng, Preethi Krishnan, Sarah Kopecky‐Bromberg, Jens Kort, Federico J. Mensa – 20 November 2017 – Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options.
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure
Chetan Kalal, Akash Shukla, Ravi Mohanka, Mihir Vora, Priyesh Patel, Samir Shah – 20 November 2017
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice
Esther Nuñez‐Durán, Mariam Aghajan, Manoj Amrutkar, Silva Sütt, Emmelie Cansby, Sheri L. Booten, Andrew Watt, Marcus Ståhlman, Norbert Stefan, Hans‐Ulrich Häring, Harald Staiger, Jan Borén, Hanns‐Ulrich Marschall, Margit Mahlapuu – 20 November 2017 – Nonalcoholic fatty liver disease (NAFLD) contributes to the pathogenesis of type 2 diabetes and cardiovascular disease, and patients with nonalcoholic steatohepatitis (NASH) are also at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma.